SCHEMBL6445516

SCHEMBL6445516

COc1cc2c(cc1OC)[C@@H]1CCCC[C@@H]1N=C2c1cc2cccc(OC)c2o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.42
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 5/20 0.41
RAB9A P51151 3/20 0.41
HPGD P15428 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ADORA2A P29274 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
NPC1 O15118 2/20 0.41
PKM P14618 2/20 0.41
ADORA1 P30542 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ADORA2B P29275 1/20 0.40
MAPT P10636 3/20 0.40
APOBEC3G Q9HC16 1/20 0.40
F2RL3 Q96RI0 3/20 0.39
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445527 1.00 FGFR1 (0.42) FGFR1KDM4EALDH1A1RAB9AHPGD
SCHEMBL6445522 1.00 FGFR1 (0.42) FGFR1KDM4EALDH1A1RAB9AHPGD
SCHEMBL6442559 0.86 LMNA (0.39) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL6442566 0.86 LMNA (0.39) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL6442562 0.86 LMNA (0.39) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL6441625 0.80 APP (0.40) KDM4EMEN1KMT2ACYP1A2HSD17B10
SCHEMBL6441620 0.80 APP (0.40) KDM4EMEN1KMT2ACYP1A2HSD17B10
SCHEMBL6441617 0.80 APP (0.40) KDM4EMEN1KMT2ACYP1A2HSD17B10
SCHEMBL6441615 0.79 ALDH1A1 (0.39) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL6441610 0.79 ALDH1A1 (0.39) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303506-B1 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2005-02-02 EP claimed
US-6884802-B2 6-heteroarylphenanthridines ALTANA PHARMA AG (DE) 2005-04-26 US disclosed
EP-1303506-B1 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2005-02-02 EP disclosed
US-20040038979-A1 Treating airway disorders such as asthma. ALTANA PHARMA AG (DE) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038979-A1 Treating airway disorders such as asthma. PTGER4, PDE4B, PDE4A FGFR1 1427/4885KDM4E 2186/4885ALDH1A1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.